Latest News in the pharma Industry

Top Stories

BMS to Acquire Inhibitex for HCV Market

BMS to Acquire Inhibitex for HCV Market

9 Jan 2012

Bristol-Myers Squibb will acquire Inhibitex with an aggregate purchase price of approximately $2.5 billion.

Read more 
GSK Licenses RA Drug CCX354 from ChemoCentryx

GSK Licenses RA Drug CCX354 from ChemoCentryx

9 Jan 2012

ChemoCentryx will receive an option exercise fee of $25 million and will be eligible for further regulatory and sales milestone payments, as well as royalties on sales.

Read more 
AnaptysBio Forms Alliances with Two Partners for Antibodies

AnaptysBio Forms Alliances with Two Partners for Antibodies

9 Jan 2012

Each partner will receive worldwide rights to develop and commercialize a limited number of antibodies against each therapeutic target generated by AnaptysBio.

Read more 
AiCuris Receives Orphan Drug Designation for Letermovir

AiCuris Receives Orphan Drug Designation for Letermovir

6 Jan 2012

AIC246 (Letermovir) has been granted Orphan Drug Designation in the US for the prevention of HCMV viremia and disease in at risk populations.

Read more 
Boehringer Ingelheim and FORMA in R&D Alliance

Boehringer Ingelheim and FORMA in R&D Alliance

6 Jan 2012

The agreement will focus on discovering small molecule drugs against oncology-relevant protein-protein interactions.

Read more 
USP Guidelines to Facilitate Supply Chain Integrity

USP Guidelines to Facilitate Supply Chain Integrity

6 Jan 2012

The proposed guidelines cover five main areas: Good Importation Practices, Counterfeit Drugs and Medical Devices, Best Practices to Combat Counterfeit Drug and Medical Devices, Diversion and Theft, and Natural Disasters.

Read more 
AAIPharma Acquires Celsis Analytical Services

AAIPharma Acquires Celsis Analytical Services

5 Jan 2012

The combined entity offers a comprehensive portfolio of methods validation and testing services for biotechnology, pharmaceutical and consumer products manufacturers, raw materials suppliers and manufacturers of agricultural and veterinary medicine pro...

Read more 
Ironwood and Bionomics Sign Compound Agreement

Ironwood and Bionomics Sign Compound Agreement

5 Jan 2012

The companies will collaborate on initial research and Ironwood will be responsible for worldwide development and commercialization of all products incorporating BNC210 or other licensed compounds.

Read more 
Biogen Idec & Isis in Global Antisense Program

Biogen Idec & Isis in Global Antisense Program

5 Jan 2012

Biogen Idec has the option to license ISIS-SMNRx until completion of the first successful Phase II/III trial.

Read more 
BioInvent & Servier Form Antibody Collaboration

BioInvent & Servier Form Antibody Collaboration

5 Jan 2012

Servier will have access to BioInvent's in-house pre-clinical capacities in selecting an antibody candidate for development.

Read more 
Isotechnika Signs License Agreement with Vifor

Isotechnika Signs License Agreement with Vifor

4 Jan 2012

Isotechnika has inked a deal with Swiss-based drug maker Vifor to commercialize the company’s lead drug candidate voclosporin for treatment of lupus.

Read more 
Teva Announces New CEO

Teva Announces New CEO

4 Jan 2012

Teva has named Dr. Jeremy Levin, a former senior executive at Bristol-Myers Squibb, to succeed Shlomo Yanai as new CEO in May.

Read more